133 related articles for article (PubMed ID: 16531720)
41. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
42. [Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Itoh K; Minami H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2141-3. PubMed ID: 16352946
[TBL] [Abstract][Full Text] [Related]
43. Feasibility of adjuvant chemotherapy for breast cancer patients.
Imoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):310-5. PubMed ID: 9390207
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant chemotherapy of breast cancer.
Garces CA; Cance WG
Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
[TBL] [Abstract][Full Text] [Related]
45. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
46. [Complete regression of breast cancer and its lung metastases after chemohormonotherapy].
Borisov VI; Vorob'ev AN; Stsetsevich NV; Ass NIa
Sov Med; 1986; (12):123-4. PubMed ID: 3563699
[No Abstract] [Full Text] [Related]
47. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
48. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
49. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
50. The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer.
Glück S
Breast Cancer; 2001; 8(4):321-8. PubMed ID: 11791125
[TBL] [Abstract][Full Text] [Related]
51. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
[TBL] [Abstract][Full Text] [Related]
52. [No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].
Heidemann E
Strahlenther Onkol; 1998 May; 174(5):290-1. PubMed ID: 9614963
[No Abstract] [Full Text] [Related]
53. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
55. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
[TBL] [Abstract][Full Text] [Related]
56. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
57. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
59. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Di Marco B; Cirillo F; Tampellini M; Bolsi G; Aguggini S; Betri E; Filippini L; Bertoli A; Alquati P; Dogliotti L
Int J Oncol; 1998 Aug; 13(2):385-90. PubMed ID: 9664137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
